Last reviewed · How we verify

American Scitech International — Portfolio Competitive Intelligence Brief

American Scitech International pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
R-mabHDI and ABVD R-mabHDI and ABVD phase 3 Monoclonal antibody + chemotherapy combination Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AryoGen Pharmed Co. · 1 shared drug class
  2. Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 shared drug class
  3. Cinnagen · 1 shared drug class
  4. Fondazione Italiana Linfomi - ETS · 1 shared drug class
  5. Fujian Medical University · 1 shared drug class
  6. Nordic Lymphoma Group · 1 shared drug class
  7. Prof. Dr. M. Dreyling (co-chairman) · 1 shared drug class
  8. Shandong Provincial Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for American Scitech International:

Cite this brief

Drug Landscape (2026). American Scitech International — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/american-scitech-international. Accessed 2026-05-16.

Related